Latest Multiple myeloma Stories
PETACH TIKVA, Israel, April 15, 2015 /PRNewswire/ -- OWC Pharmaceutical Research Corp.
MADRID, April 14, 2015 /PRNewswire/ -- - Combination of the anticancer drug PM1183 with PARP inhibitors and doxorubicin results in a synergistic
TAMPA, Fla., April 1, 2015 /PRNewswire/ -- Oxis Biotech, Inc. (OXIS), a wholly owned subsidiary of Oxis International, Inc.
Second Milestone Achieved For Patient-Driven, Crowdsourced Funding Initiative SALT LAKE CITY, March 31, 2015 /PRNewswire-USNewswire/ -- The Myeloma Crowd Research Initiative (MCRI)
Application Designed to Support Conversion of Accelerated to Full FDA Approval THOUSAND OAKS, Calif., March 30, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the U.S.
NORTH HOLLYWOOD, Calif., March 27, 2015 /PRNewswire/ -- The International Myeloma Foundation (IMF) - improving the quality of life of myeloma patients while working toward prevention and a cure
TAMPA, Fla., March 26, 2015 /PRNewswire/ -- Oxis Biotech, Inc. (OXIS), a wholly owned subsidiary of Oxis International, Inc.
FIRST MILESTONE ACHIEVED FOR PATIENT-DRIVEN, CROWDSOURCED FUNDING INITIATIVE SALT LAKE CITY, March 16, 2015 /PRNewswire-USNewswire/ -- For the first time in myeloma history, researchers
NESS ZIONA, Israel, March 16, 2015 /PRNewswire/ -- - Recognition of the unmet medical need and high therapeutic potential of ImMucin in Multiple
WOONSOCKET, R.I., March 12, 2015 /PRNewswire/ -- MultiCell Immunotherapeutics, Inc. (MCIT), a majority owned subsidiary of MultiCell Technologies, Inc.
- Growing in low tufty patches.